Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Clinical trial NCT04291092 · UNKNOWN

Trial details

NCT number: NCT04291092
Sponsor: Zhejiang Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

NSCLC Stage IV Brain Metastases Immunotherapy

Start date: 2020-01-01
Primary completion: 2022-06-30
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.